March 28, 2019
Japan’s key reimbursement policy panel on March 27 approved the health ministry’s proposal to use the current drug pricing and listing rules for newly approved CAR-T cell therapy Kymriah (tisagenlecleucel) and HGF gene therapy Collategene (beperminogene perplasmid). The two products,...read more